Galectin-3 as a marker of kidney damage in monoclonal gammopathy of undetermined significance and multiple myeloma in residents of the Gomel region of Belarus
Abstract
Multiple myeloma (MM) is a tumor from plasma cells, which in its development passes the stage of monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma. It is characterized by bone marrow infiltration, the presence of foci of destructive lesions, hypercalcemia, and impaired renal function. Renal failure of varying degrees of manifestation occurs in almost half of patients with newly diagnosed MM.In MM with light chain secretion, the presence of renal failure is almost always associated with a monoclonal protein, and in these cases a kidney biopsy is usually not needed to confirm the cause of the lesion. At the same time, MGUS patients with chronic renal failure (CRF) and monoclonal protein require renal biopsy to exclude amyloidosis, hypertensive or diabetic nephropathy.Renal biopsy is associated with an increased expectancy of complications; therefore, it is urgent to search for new markers for non-invasive determination of neoplastic kidney damage. The article presents the results of the study of the role of galectin-3 as a marker of kidney damage in patients with MGUS and newly diagnosed MM of the Gomel region.
About the Authors
Zh. M. Kozich
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
V. N. Martinkov
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
Yu. I. Yarets
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
Zh. N. Pugacheva
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
D. A. Blizin
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
L. A. Smirnova
УО «Белорусская медицинская академия последипломного образования»
Russian Federation
Russian Federation
References
1. Siegel, R.L. Cancer statistics, 2019 / R.L. Siegel, K.D. Miller, A. Jemal // CA: a cancer journal for clinicians. - 2019. - Vol. 69, № 1. - P. 7-34.
2. Rajkumar, S.V. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management / S.V. Rajkumar // American journal of hematology. - 2014. - Vol. 89, № 10. - P. 999-1009.
3. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. / R.A. Kyle [et al.] // The New England journal of medicine. - 2018. - Vol. 378, № 3. - P. 241- 249.
4. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study / O. Landgren [et al.] // Blood. - 2009. - Vol. 113, № 22. - P. 5412- 5417.
5. Bridoux, F. Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial / F. Bridoux, J.-P. Fermand // Advances in chronic kidney disease. - 2012. - Т. 19, № 5. - С. 333- 341.
6. Yang, R.-Y. Galectins: structure, function and therapeutic potential / R.- Y. Yang, G.A. Rabinovich, F.-T. Liu // Expert reviews in molecular medicine. - 2008. - Т. 10. - С. e17.
7. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review) / R. Dong [et al.] // International journal of molecular medicine. - 2018. - Т. 41, № 2. - С. 599-614.
8. Storti, P. Role of Galectins in Multiple Myeloma / P. Storti, V. Marchica, N. Giuliani // International journal of molecular sciences. - 2017. - Vol. 18, № 12. - P. 1-7.
9. Самура, Б.Б. Прогностическая роль циркулирующего галектина-3 у пациентов со множественной миеломой в ремиссии / Б.Б. Самура // Запорожский медицинский журнал. - 2015. - № 4. - С. 11-16.
10. The Role of CD27, CD40 and CD117 in the Diagnosis and Prognosis of Multiple Myeloma Established by Flow Cytometry / G.De Tullio [et al.] // Blood. - 2014. - Vol. 124, № 21. - P. 5711-5711.
11. Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease / B.R. Winkelmann [et al.] // Pharmacogenomics. - 2001. - Т. 2, 1 Suppl 1. - С. S1-73.
12. Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies / C. Drechsler [et al.] // Journal of the American Society of Nephrology : JASN. - 2015. - Т. 26, № 9. - С. 2213-2221.
13. Up-Regulation of Galectin-3 in Acute Renal Failure of the Rat /j. Nishiyama [et al.] // The American Journal of Pathology. - 2000. - Т. 157, № 3. - С. 815-823.
14. Leung, N. Myeloma-related kidney disease / N. Leung, S.H. Nasr // Advances in chronic kidney disease. - 2014. - Т. 21, № 1. - С. 36-47.
15. Herrera, G.A. Paraproteinemic renal diseases that involve the tubulo-interstitium / G.A. Herrera, P.W. Sanders // Contributions to nephrology. - 2007. - Т. 153. - С. 105-115.
16. Sasaki, S. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies / S. Sasaki, Q. Bao, R.C. Hughes // The Journal of pathology. - 1999. - Т. 187, № 4. - С. 481-489.
17. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. / N.C. Henderson [и др.] // The American journal of pathology. - 2008. - Т. 172, № 2. - С. 288-298.
Review
For citations:
Kozich Zh.M., Martinkov V.N., Yarets Yu.I., Pugacheva Zh.N., Blizin D.A., Smirnova L.A. Galectin-3 as a marker of kidney damage in monoclonal gammopathy of undetermined significance and multiple myeloma in residents of the Gomel region of Belarus. Medical and Biological Problems of Life Activity. 2021;(1):168-174. (In Russ.)
Views: 181
Email this article 